PACIFIC EDGE LIMITED — Capital/Financing Update 2018

Nov 30, 2018

30 November 2018

==> picture [225 x 57] intentionally omitted <==

PACIFIC EDGE COMPLETES $7 MILLION PLACEMENT OF NEW SHARES

Pacific Edge Limited (NZX: PEB) ( Pacific Edge ) advises that it has completed a placement of $7m of new shares under its capital raising announced on 29 November 2018 ( Placement ).

Chair of Pacific Edge, Chris Gallaher, said: “We are pleased to have completed the first phase of our capital raising which will provide funding to progress our commercial objectives and become cash flow positive as soon as possible.”

Trading of Pacific Edge on the NZX is expected to resume at market open. The new shares under the Placement are expected to be allotted and commence trading on the NZX Main Board on Wednesday 5 December 2018.

All New Zealand resident shareholders of Pacific Edge will have the opportunity to subscribe for additional Pacific Edge shares at no greater than the placement price ($0.35) in due course. The full terms and conditions of the Share Purchase Plan (SPP) will be contained in an offer document which will be distributed to all eligible shareholders after the proposed record date.

Share Purchase Plan Timetable
Record Date of SPP	7 December
OpeningDate for SPP	10 December
ClosingDate for SPP	25 January2019
Allotment and Settlement of SPP shares	31 January2019

All dates and times are indicative only and subject to change.

• ENDS -

David Darling Chief Executive Officer Pacific Edge Ltd

Cell: +64 21 797 981 Ph: +64 3 4795 800

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

30 November 2018

==> picture [225 x 57] intentionally omitted <==

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires lifelong surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.